Header Logo

WEEI-CHIN LIN

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDepartment of Molecular & Cellular Biology
    DivisionMolecular & Cellular Biology

    TitleProfessor
    InstitutionBaylor College of Medicine
    DepartmentDuncan Cancer Center
    DivisionCancer Center


    Collapse Biography 
    Collapse awards and honors
    2021 - 2023Pilot Study Award, Rivkin Center for Ovarian Cancer
    2016 - 2017Pilot Study Award, Rivkin Center for Ovarian Cancer
    2014 - 2019BCM Oncology Scholars Training Program (T32), NIH/NCI
    2013Dan L. Duncan Cancer Center pilot project award, Baylor College of Medicine
    2012Breast SPORE Translational Research Award, Baylor College of Medicine
    2010Dan Duncan Professorship of Oncology, Baylor College of Medicine, Baylor College of Medicine
    2007 - 2014America’s Top Doctors (Hematology), Castle Connolly Medical Ltd.
    2007 - 2011America’s Top Doctors for Cancer, Castle Connolly Medical Ltd.
    2006 - 2011Leukemia & Lymphoma Society Scholar, University of Alabama at Birmingham
    2002 - 2005General Motors Cancer Research Scholar, University of Alabama at Birmingham
    2001 - 2004Breast SPORE Career Development Award, UAB, University of Alabama at Birmingham
    2001 - 2004Howard Hughes Medical Institute Junior Faculty Development Award, University of Alabama at Birmingham
    1998 - 2001Physician Scientist Award, Damon Runyon-Walter Winchell Foundation , Duke University
    1998American Society of Hematology Fellow Scholar Award
    1993the Martin and Carol Macht Research Prize, Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine
    1979 - 1986Book Coupon Awards, National Taiwan University College of Medicine, National Taiwan University

    Collapse Research 
    Collapse research activities and funding
    BC230488     (LIN, WEEI-CHIN)Mar 1, 2024 - Feb 28, 2027
    Department of Defense Breast Cancer Research Program Breakthrough Award 2 –Funding Level 2
    Synthetic Lethal Combination Targeting TopBP1 and Arachidonic Acid Pathway in Breast Cancer
    Role: Principal Investigator
    1R01CA269971-01A1     (LIN, WEEI-CHIN)Apr 17, 2023 - Mar 31, 2028
    NIH/NCI
    14-3-3tau drives estrogen receptor loss and breast cancer progression
    Role: Principal Investigator
    R01CA269971     (LIN, WEEI-CHIN)Apr 17, 2023 - Mar 31, 2028
    NIH
    14-3-3tau drives estrogen receptor loss and breast cancer progression
    Role: Principal Investigator
    LC210369     (LIN, WEEI-CHIN)Aug 1, 2022 - Jul 31, 2024
    Department of Defense Lung Cancer Research Program Idea Development Award-Established Investigator
    New therapeutics targeting MYC and immune escape in lung cancer
    Role: Principal Investigator
    BC210863     (LIN, WEEI-CHIN)May 15, 2022 - May 14, 2025
    Department of Defense Breast Cancer Research Program Expansion Award
    Novel Synthetic Lethal Therapies for Triple-Negative Breast Cancer
    Role: Principal Investigator
    2R01CA203824-06A1     (LIN, WEEI-CHIN)Feb 1, 2022 - Jan 31, 2027
    NIH/NCI
    Novel therapeutics for targeting checkpoint dysfunction in cancer
    Role: Principal Investigator
    Pilot Award     (LIN, WEEI-CHIN)Apr 1, 2021 - Mar 31, 2023
    Rivkin Center for Ovarian Cancer Pilot Award
    Novel approaches to target MYC in ovarian cancer
    Role: Principal Investigator
    BC181104     (LIN, WEEI-CHIN)Aug 1, 2019 - Jul 31, 2023
    Department of Defense Breast Cancer Research Program Expansion Award
    Title: Inducing BRCAness to synergize with PARP inhibitors in breast cancer
    Role: Principal Investigator
    BC171396     (LIN, WEEI-CHIN)Sep 30, 2018 - Sep 29, 2022
    Department of Defense Breast Cancer Research Program Breakthrough Award 2 –Funding Level 2
    Exploiting a new Achilles’ heel of mutant p53 in breast cancer
    Role: Principal Investigator
    R01CA203824     (LIN, WEEI-CHIN)Dec 15, 2016 - Jan 31, 2027
    NIH
    Novel therapeutics for targeting checkpoint dysfunction in cancer
    Role: Principal Investigator
    R21CA198041     (LIN, WEEI-CHIN)Jun 1, 2016 - May 31, 2019
    NIH
    New mechanisms of breast cancer metastasis and loss of estrogen receptor driven by 14-3-3
    Role: Principal Investigator
    Pilot Award     (LIN, WEEI-CHIN)Apr 1, 2016 - Mar 31, 2017
    Rivkin Center for Ovarian Cancer
    Target a new mechanism of checkpoint defect in ovarian cancer
    Role: Principal Investigator
    BC133678     (LIN, WEEI-CHIN)Sep 30, 2014 - Sep 29, 2018
    Department of Defense Breast Cancer Research Program Breakthrough Award 2 –Funding Level 2
    Targeting a convergent point of multiple oncogenic pathways in breast cancer, a new paradigm for targeted therapy
    Role: Principal Investigator
    OC130395     (LIN, WEEI-CHIN)Sep 15, 2014 - Sep 14, 2017
    Department of Defense Ovarian Cancer Research Program
    Novel approaches to target mutant p53 gain-of-function in ovarian cancer
    Role: Principal Investigator
    T32CA174647     (LIN, WEEI-CHIN)Aug 5, 2014 - Jul 31, 2020
    NIH
    BCM Oncology Scholars Training Program
    Role: Principal Investigator
    R01CA138641     (LIN, WEEI-CHIN)Apr 1, 2010 - Jan 31, 2016
    NIH
    Therapeutic Targeting of Oncogenic Stress in Cancer Treatment
    Role: Principal Investigator
    BC084561     (LIN, WEEI-CHIN)Jun 1, 2009 - Mar 31, 2014
    Department of Defense Breast Cancer Research Program
    Regulation of p21 turnover by 14-3-3tau: a basis for novel therapeutic strategies against breast cancer
    Role: Principal Investigator
    The Leukemia & Lymphoma Society Scholar Award     (LIN, WEEI-CHIN)Jul 1, 2006 - Jun 30, 2011
    The Leukemia & Lymphoma Society
    The function and regulation of TopBP1 in growth and DNA damage response
    Role: Principal Investigator
    BC031962     (LIN, WEEI-CHIN)Mar 25, 2004 - Mar 24, 2008
    Department of Defense
    The Role of TopBP1 in Breast Cancer
    Role: Principal Investigator
    R01CA100857     (LIN, WEEI-CHIN)Apr 1, 2003 - Feb 28, 2021
    NIH
    The ATM/E2F1 Pathway in DNA Damage and Growth Control
    Role: Principal Investigator
    General Motors Cancer Research Scholar     (LIN, WEEI-CHIN)Jan 7, 2002 - Jan 7, 2005
    General Motors Cancer Research Scholars Program
    Regulation of E2F1 by ATM
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lin FT, Liu K, Garan LAW, Folly-Kossi H, Song Y, Lin SJ, Lin WC. A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. Proc Natl Acad Sci U S A. 2023 Oct 31; 120(44):e2307793120. PMID: 37878724; PMCID: PMC10622895.
      Citations:    Fields:    Translation:HumansAnimals
    2. Folly-Kossi H, Graves JD, Garan LAW, Lin FT, Lin WC. DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors. Cancer Res Commun. 2023 10 16; 3(10):2096-2112. PMID: 37756561; PMCID: PMC10578204.
      Citations:    Translation:Humans
    3. Chen SM, Phuc PT, Nguyen PA, Burton W, Lin SJ, Lin WC, Lu CY, Hsu MH, Cheng CT, Hsu JC. A novel prediction model of the risk of pancreatic cancer among diabetes patients using multiple clinical data and machine learning. Cancer Med. 2023 10; 12(19):19987-19999. PMID: 37737056; PMCID: PMC10587954.
      Citations: 2     Fields:    Translation:Humans
    4. Lin WC, Lin FT. Super-enhanced MARCO variant drives triple-negative breast cancer progression. Proc Natl Acad Sci U S A. 2022 12 13; 119(50):e2217953119. PMID: 36469785; PMCID: PMC9897437.
      Citations:    Fields:    Translation:Humans
    5. Liu SD, Lin SJ, Ray CY, Lin FT, Lin WC, Wang LH. Associations of Warfarin Use with Risks of Ischemic Cerebrovascular Events and Major Bleeding in Patients with Hyperthyroidism-Related Atrial Fibrillation. Biomedicines. 2022 Oct 22; 10(11). PMID: 36359190; PMCID: PMC9687236.
      Citations:    
    6. Garan LAW, Xiao Y, Lin WC. 14-3-3t drives estrogen receptor loss via ERa36 induction and GATA3 inhibition in breast cancer. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2209211119. PMID: 36252018; PMCID: PMC9618134.
      Citations: 1     Fields:    Translation:HumansCells
    7. Lin WK, Lin SJ, Lee WR, Lin CC, Lin WC, Chang HC, Cheng CT, Hsu JC. Effectiveness and Safety of Immunosuppressants and Biological Therapy for Chronic Spontaneous Urticaria: A Network Meta-Analysis. Biomedicines. 2022 Sep 01; 10(9). PMID: 36140253; PMCID: PMC9496015.
      Citations:    
    8. Ho SR, Lee YC, Ittmann MM, Lin FT, Chan KS, Lin WC. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021 11 01; 520:344-360. PMID: 34400221; PMCID: PMC9420248.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    9. Liu K, Graves JD, Lin FT, Lin WC. Correction: Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in?cancer. J Biol Chem. 2021 Jul; 297(1):100924. PMID: 34218139; PMCID: PMC8259050.
      Citations:    Fields:    
    10. Liu K, Graves JD, Lin FT, Lin WC. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. J Biol Chem. 2021 Jan-Jun; 296:100382. PMID: 33556369; PMCID: PMC7949146.
      Citations: 2     Fields:    Translation:HumansCells
    11. Xiao Y, Lin FT, Lin WC. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer. Proc Natl Acad Sci U S A. 2021 01 19; 118(3). PMID: 33408251; PMCID: PMC7826354.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    12. Turin CG, Ting K, Bradshaw A, Dunham SR, Nunez-Wallace K, Patel SM, Dangayach P, Holdener S, Lin WC. Central nervous system intravascular lymphoma leading to rapidly progressive dementia. Proc (Bayl Univ Med Cent). 2021 Jan 11; 34(3):373-375. PMID: 33953465; PMCID: PMC8059917.
      Citations:    
    13. Graves JD, Lee YJ, Liu K, Li G, Lin FT, Lin WC. E2F1 sumoylation as a protective cellular mechanism in oxidative stress response. Proc Natl Acad Sci U S A. 2020 06 30; 117(26):14958-14969. PMID: 32541040; PMCID: PMC7334650.
      Citations: 4     Fields:    Translation:HumansCells
    14. Liu K, Graves JD, Lee YJ, Lin FT, Lin WC. Cell Cycle-Dependent Switch of TopBP1 Functions by Cdk2 and Akt. Mol Cell Biol. 2020 03 30; 40(8). PMID: 31964753; PMCID: PMC7108819.
      Citations: 5     Fields:    Translation:HumansCells
    15. Lee YJ, Ho SR, Graves JD, Xiao Y, Huang S, Lin WC. CGRRF1, a growth suppressor, regulates EGFR ubiquitination in breast cancer. Breast Cancer Res. 2019 12 04; 21(1):134. PMID: 31801577; PMCID: PMC6894136.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    16. Ho SR, Lin WC. RNF144A sustains EGFR signaling to promote EGF-dependent cell proliferation. J Biol Chem. 2018 10 19; 293(42):16307-16323. PMID: 30171075; PMCID: PMC6200932.
      Citations: 5     Fields:    Translation:HumansCells
    17. . Method of treating cancer that overexpresses TopBP1. 2017. View Publication.
    18. Liu K, Lin FT, Graves JD, Lee YJ, Lin WC. Mutant p53 perturbs DNA replication checkpoint control through TopBP1 and Treslin. Proc Natl Acad Sci U S A. 2017 05 09; 114(19):E3766-E3775. PMID: 28439015; PMCID: PMC5441733.
      Citations: 19     Fields:    Translation:HumansCells
    19. Lin FT, Lin VY, Lin VT, Lin WC. TRIP6 antagonizes the recruitment of A20 and CYLD to TRAF6 to promote the LPA2 receptor-mediated TRAF6 activation. Cell Discov. 2016; 2. PMID: 27134758; PMCID: PMC4850058.
      Citations: 7     
    20. Mahanic CS, Budhavarapu V, Graves JD, Li G, Lin WC. Regulation of E2 promoter binding factor 1 (E2F1) transcriptional activity through a deubiquitinating enzyme, UCH37. J Biol Chem. 2015 Oct 30; 290(44):26508-22. PMID: 26396186; PMCID: PMC4646310.
      Citations: 16     Fields:    Translation:HumansCells
    21. Ho SR, Lee YJ, Lin WC. Regulation of RNF144A E3 Ubiquitin Ligase Activity by Self-association through Its Transmembrane Domain. J Biol Chem. 2015 Sep 18; 290(38):23026-38. PMID: 26216882; PMCID: PMC4645615.
      Citations: 9     Fields:    Translation:HumansCells
    22. Chowdhury P, Lin GE, Liu K, Song Y, Lin FT, Lin WC. Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. Nat Commun. 2014 Nov 17; 5:5476. PMID: 25400145; PMCID: PMC4254804.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    23. Xiao Y, Lin VY, Ke S, Lin GE, Lin FT, Lin WC. 14-3-3t promotes breast cancer invasion and metastasis by inhibiting RhoGDIa. Mol Cell Biol. 2014 Jul; 34(14):2635-49. PMID: 24820414; PMCID: PMC4097670.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    24. Ho SR, Mahanic CS, Lee YJ, Lin WC. RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage. Proc Natl Acad Sci U S A. 2014 Jul 01; 111(26):E2646-55. PMID: 24979766; PMCID: PMC4084471.
      Citations: 27     Fields:    Translation:HumansCells
    25. Liu K, Graves JD, Scott JD, Li R, Lin WC. Akt switches TopBP1 function from checkpoint activation to transcriptional regulation through phosphoserine binding-mediated oligomerization. Mol Cell Biol. 2013 Dec; 33(23):4685-700. PMID: 24081328; PMCID: PMC3838014.
      Citations: 20     Fields:    Translation:HumansCells
    26. Lin VT, Lin VY, Lai YJ, Chen CS, Liu K, Lin WC, Lin FT. TRIP6 regulates p27 KIP1 to promote tumorigenesis. Mol Cell Biol. 2013 Apr; 33(7):1394-409. PMID: 23339869; PMCID: PMC3624266.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    27. Budhavarapu VN, White ED, Mahanic CS, Chen L, Lin FT, Lin WC. Regulation of E2F1 by APC/C Cdh1 via K11 linkage-specific ubiquitin chain formation. Cell Cycle. 2012 May 15; 11(10):2030-8. PMID: 22580462; PMCID: PMC3359126.
      Citations: 28     Fields:    Translation:HumansCells
    28. Liu K, Ling S, Lin WC. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol. 2011 Nov; 31(22):4464-81. PMID: 21930790; PMCID: PMC3209258.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    29. Ling S, Lin WC. EDD inhibits ATM-mediated phosphorylation of p53. J Biol Chem. 2011 Apr 29; 286(17):14972-82. PMID: 21383020; PMCID: PMC3083215.
      Citations: 22     Fields:    Translation:HumansCells
    30. Hanski ML, Stehr J, Jebautzke B, Fechner H, Yokoyama KK, Lin WC, Zeitz M, Hanski C, Bhonde MR, Peir?-Jord?n R. Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38. Int J Cancer. 2010 Jun 15; 126(12):2813-25. PMID: 19739070; PMCID: PMC4205106.
      Citations: 2     Fields:    Translation:HumansCells
    31. Wang B, Ling S, Lin WC. 14-3-3Tau regulates Beclin 1 and is required for autophagy. PLoS One. 2010 Apr 29; 5(4):e10409. PMID: 20454448; PMCID: PMC2861590.
      Citations: 30     Fields:    Translation:HumansCells
    32. Wang B, Liu K, Lin HY, Bellam N, Ling S, Lin WC. 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol. 2010 Mar; 30(6):1508-27. PMID: 20086099; PMCID: PMC2832502.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    33. Paik JC, Wang B, Liu K, Lue JK, Lin WC. Regulation of E2F1-induced apoptosis by the nucleolar protein RRP1B. J Biol Chem. 2010 Feb 26; 285(9):6348-63. PMID: 20040599; PMCID: PMC2825430.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    34. Liu K, Bellam N, Lin HY, Wang B, Stockard CR, Grizzle WE, Lin WC. Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer. Mol Cell Biol. 2009 May; 29(10):2673-93. PMID: 19289498; PMCID: PMC2682038.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    35. Yang SZ, Lin FT, Lin WC. MCPH1/BRIT1 cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008 Sep; 9(9):907-15. PMID: 18660752; PMCID: PMC2529348.
      Citations: 42     Fields:    Translation:HumansCells
    36. Lin FT, Lai YJ, Makarova N, Tigyi G, Lin WC. The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival. J Biol Chem. 2007 Dec 28; 282(52):37759-69. PMID: 17965021; PMCID: PMC3496872.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    37. Lai YJ, Lin WC, Lin FT. PTPL1/FAP-1 negatively regulates TRIP6 function in lysophosphatidic acid-induced cell migration. J Biol Chem. 2007 Aug 17; 282(33):24381-7. PMID: 17591779; PMCID: PMC3923842.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    38. Liu K, Paik JC, Wang B, Lin FT, Lin WC. Regulation of TopBP1 oligomerization by Akt/PKB for cell survival. EMBO J. 2006 Oct 18; 25(20):4795-807. PMID: 17006541; PMCID: PMC1618094.
      Citations: 50     Fields:    Translation:HumansAnimalsCells
    39. Lai YJ, Chen CS, Lin WC, Lin FT. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol Cell Biol. 2005 Jul; 25(14):5859-68. PMID: 15988003; PMCID: PMC1168818.
      Citations: 36     Fields:    Translation:AnimalsCells
    40. Wang B, Liu K, Lin FT, Lin WC. A role for 14-3-3 tau in E2F1 stabilization and DNA damage-induced apoptosis. J Biol Chem. 2004 Dec 24; 279(52):54140-52. PMID: 15494392; PMCID: PMC3904440.
      Citations: 51     Fields:    Translation:Cells
    41. Luo Y, Lin FT, Lin WC. ATM-mediated stabilization of hMutL DNA mismatch repair proteins augments p53 activation during DNA damage. Mol Cell Biol. 2004 Jul; 24(14):6430-44. PMID: 15226443; PMCID: PMC434232.
      Citations: 27     Fields:    Translation:HumansCells
    42. Liu K, Luo Y, Lin FT, Lin WC. TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survival. Genes Dev. 2004 Mar 15; 18(6):673-86. PMID: 15075294; PMCID: PMC387242.
      Citations: 78     Fields:    Translation:Cells
    43. Xu J, Lai YJ, Lin WC, Lin FT. TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor. J Biol Chem. 2004 Mar 12; 279(11):10459-68. PMID: 14688263; PMCID: PMC3904432.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    44. Liu K, Lin FT, Ruppert JM, Lin WC. Regulation of E2F1 by BRCT domain-containing protein TopBP1. Mol Cell Biol. 2003 May; 23(9):3287-304. PMID: 12697828; PMCID: PMC153207.
      Citations: 76     Fields:    Translation:HumansCells
    45. Lin WC, Lin FT, Nevins JR. Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001 Jul 15; 15(14):1833-44. PMID: 11459832; PMCID: PMC312742.
      Citations: 186     Fields:    Translation:HumansAnimalsCells
    46. Lin WC, Telen MJ. Cardiac metastasis from a transitional cell carcinoma: a case report. Med Oncol. 2000 May; 17(2):147-50. PMID: 10871822.
      Citations: 3     Fields:    Translation:Humans
    47. Lin WC, Moore JO, Mann KP, Traweek ST, Smith C. Post transplant CD8+ gammadelta T-cell lymphoma associated with human herpes virus-6 infection. Leuk Lymphoma. 1999 Apr; 33(3-4):377-84. PMID: 10221519.
      Citations: 3     Fields:    Translation:HumansCells
    48. Desiderio S, Lin WC, Li Z. The cell cycle and V(D)J recombination. Curr Top Microbiol Immunol. 1996; 217:45-59. PMID: 8787617.
      Citations: 29     Fields:    Translation:Cells
    49. Lin WC, Desiderio S. V(D)J recombination and the cell cycle. Immunol Today. 1995 Jun; 16(6):279-89. PMID: 7662097.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    50. Lin WC, Desiderio S. Cell cycle regulation of V(D)J recombination-activating protein RAG-2. Proc Natl Acad Sci U S A. 1994 Mar 29; 91(7):2733-7. PMID: 8146183; PMCID: PMC43444.
      Citations: 74     Fields:    Translation:AnimalsCells
    51. Oltz EM, Alt FW, Lin WC, Chen J, Taccioli G, Desiderio S, Rathbun G. A V(D)J recombinase-inducible B-cell line: role of transcriptional enhancer elements in directing V(D)J recombination. Mol Cell Biol. 1993 Oct; 13(10):6223-30. PMID: 8413222; PMCID: PMC364681.
      Citations: 29     Fields:    Translation:AnimalsCells
    52. Lin WC, Desiderio S. Regulation of V(D)J recombination activator protein RAG-2 by phosphorylation. Science. 1993 May 14; 260(5110):953-9. PMID: 8493533.
      Citations: 66     Fields:    Translation:HumansAnimalsCells
    53. Lin LY, Lin WC, Huang PC. Pigeon metallothionein consists of two species. Biochim Biophys Acta. 1990 Feb 09; 1037(2):248-55. PMID: 2407296.
      Citations: 3     Fields:    Translation:AnimalsCells
    LIN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (307)
    Explore
    _
    Co-Authors (9)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _